Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP*experience

Publisher Website
Google Scholar
Abstract
One hundred and forty‐seven patients aged PP18 months versus 6·6±3·17% for those with CR P<0·0001).Projected disease‐free survival (DFS ±SE) was 15·4±4·61% at 55 months for all responders and 43·3±14·34% at 52 months for allografted patients. Projected overall probability of survival ±SE for all patients was 18·8±4·13% at 56 months.This study confirms the efficacy of IDA plus IDARA‐C in poor‐risk ALL patients. A more intensive post‐remission therapy or alternative approach must be designed to improve long‐term results.